Godwin, Colin D.
Laszlo, George S.
Wood, Brent L.
Correnti, Colin E.
Bates, Olivia M.
Garling, Eliotte E.
Mao, Zhengwei J.
Beddoe, Mary E.
Lunn, Margaret C.
Humbert, Olivier
Kiem, Hans-Peter http://orcid.org/0000-0001-5949-4947
Walter, Roland B.
Article History
Received: 14 October 2019
Revised: 14 January 2020
Accepted: 10 February 2020
First Online: 18 February 2020
Compliance with ethical standards
:
: HPK is a consultant to and has ownership interests with Rocket Pharma and Homology Medicines and is a consultant to CSL Behring and Magenta Therapeutics. RBW received laboratory research grants and/or clinical trial support from Agios, Amgen, Aptevo Therapeutics, Arog, BioLineRx, Jazz, Pfizer, Seattle Genetics, and Selvita; has ownership interests with Amphivena Therapeutics; and is (or has been) a consultant to Agios, Amphivena Therapeutics, Astellas, BiVictrix, Boehringer Ingelheim, Covagen, Emergent Biosolutions/Aptevo Therapeutics, Jazz, Kite, Pfizer, and Seattle Genetics. The other authors declare no competing financial interests.